STUDY TO EVALUATE SWITCHING FROM A REGIMEN CONSISTING OF EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE (EFV/FTC/TDF) FIXED DOSE COMBINATION (FDC) TO EMTRICITABINE/RILPIVIRINE/TENOFOVIR ALAFENAMIDE (FTC/RPV/TAF) FDC IN VIROLOGICALLY-SUPPRESSED, HIV-1 INFECTED ADULTS: